Tumor Type

France
Prostate Cancer - Adenocarcinoma
Project Profile
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
2:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

France: Assistance Publique - Hôpitaux de Paris (AP-HP)
Centre de Recherche sur les Pathologies Prostatiques (CeRePP)
Centre Hospitalier de Poitiers
Centre Hospitalier Pointe-à-Pitre/Abymes
Centre Hospitalier Régional et Universitaire de Brest
Centre Hospitalier Régional Universitaire de Lille
Fondation Synergie Lyon Cancer
INSERM U625
Institut Universitaire de Cancérologie - Université Pierre et Marie Curie (IUC-UPMC)

This study includes French Caucasian and African-Caribbean prostate cancer cases treated by radical prostatectomy. Only tumors from patients affected by an aggressive (high grade) prostate cancer are selected. All samples are reviewed by a referent pathologist. Macrodissection to isolate tumoral tissues (high grade and at least 70 % cancerous cells) and non tumoral tissues is performed. Digital images will be captured and stored for reference purposes. DNA and RNA (including miRNA) extractions from normal and tumoral tissues are performed. Germline DNA is extracted.

Sequencing & Analysis

France: Fondation Synergie Lyon Cancer
International Agency for Research on Cancer (IARC)
Spain: Centro Nacional de Análisis Genómico

Centre Nacional d'Anàlisi Genòmica (CNAG)
• Whole genome sequencing
• RNA and miRNA sequencing

International Agency for Research on Cancer (IARC)
• Whole exome sequencing

Fondation Synergie Lyon Cancer
• Methylome analyses

Complementary Studies

France: Fondation Synergie Lyon Cancer

Fondation Synergie Lyon Cancer
• Genomic analyses including SNP-CGH and transcriptomic analyses

Data Storage, Analysis & Management

France: Centre de Recherche sur les Pathologies Prostatiques (CeRePP)
Fondation Synergie Lyon Cancer

Details to follow

Project Summary

Every year about 70,000 new cases of prostate cancer are diagnosed in France and 8,700 men died from this disease. But the incidence and the rate of mortality per 100,000 men in the French West Indies are respectively 1.5x and 2x upper than the rates observed in the metropolitan France. The aim of this project is to identify, on French Caucasian and African-Caribbean men, relevant genomic events involved in prostate carcinogenesis. The project aims to identify, through an integrative approach, genomic factors which characterize or allow targeting the various phenotypes of aggressiveness of early stages of prostate cancer. The project hypothesizes that molecular events leading to aggressive (clinical progression to extraprostatic disease and hormone refractory disease) are present at the earliest stages of the disease and are modulated by microenvironment and genetic background. We propose a multiple stages study design involving firstly the generation of a primary set of genome-wide genomic data (whole genome sequencing, whole exome sequencing, RNA and miRNA sequencing) on 25 tumors of aggressive (high grade) prostate cancer samples (from 15 French Caucasian and 10 African-Caribbean men who were treated by radical prostatectomy). Among the 25 prostate cancer samples, ten will be also selected for methylation analyses. The discovery data will be analysed to catalogue differences that are observed between tumour and referent DNA. We will identify target regions (e.g. somatic mutations, structural variants, and/or singular expression patterns clustering in particular genes, genomic regions or functional pathways) for next stages of the study. Secondly, we plan to validate the clinical relevance of target regions identified on different (5) and large independent sets (500) of prostate cancers specimens according the following phenotypes stratification: (i) Caucasian versus African-Caribbean; (ii) Low grade versus high grade. (iii) Early onset versus late onset; (iv) Free survival disease versus recurrent disease; (v) Metastatic versus non metastatic disease.

Principal Investigators

• Olivier Cussenot

Lead Jurisdiction